Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic ER+ Her2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06784193
What this trial is testing

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Olema Pharmaceuticals, Inc. 180
Testing effectiveness (Phase 2)Ended earlyNCT03519178
What this trial is testing

PF-06873600 in People With Cancer

Who this might be right for
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Pfizer 155
Large-scale testing (Phase 3)Active Not RecruitingNCT06016738
What this trial is testing

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 510
Testing effectiveness (Phase 2)Study completedNCT00444535
What this trial is testing

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 52
Testing effectiveness (Phase 2)Study completedNCT03878823
What this trial is testing

Safety and Pharmacokinetics of ODM-209

Who this might be right for
Prostate Cancer MetastaticAdvanced Breast CancerCastration-resistant Prostate Cancer+1 more
Orion Corporation, Orion Pharma 38
Testing effectiveness (Phase 2)Looking for participantsNCT05601440
What this trial is testing

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Canadian Cancer Trials Group 484
Testing effectiveness (Phase 2)Ended earlyNCT03709082
What this trial is testing

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast Cancer Metastatic
University of Kansas Medical Center 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT04214288
What this trial is testing

Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

Who this might be right for
Advanced ER-Positive HER2-Negative Breast Cancer
AstraZeneca 240
Early research (Phase 1)Study completedNCT03455270
What this trial is testing

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast Cancer FemaleBreast Neoplasm+4 more
G1 Therapeutics, Inc. 107
Testing effectiveness (Phase 2)Ended earlyNCT03584009
What this trial is testing

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Who this might be right for
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 103
Large-scale testing (Phase 3)Study completedNCT01881230
What this trial is testing

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Who this might be right for
Breast TumorBreast CancerCancer of the Breast+8 more
Celgene 191
Testing effectiveness (Phase 2)Looking for participantsNCT05846789
What this trial is testing

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerEstrogen-receptor-low Breast Cancer+1 more
Kathy Miller 168
Testing effectiveness (Phase 2)Study completedNCT03321981
What this trial is testing

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Who this might be right for
Breast Cancer Metastatic
Merus B.V. 105
Large-scale testing (Phase 3)Active Not RecruitingNCT02947685
What this trial is testing

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Who this might be right for
HER-2 Positive Breast CancerEstrogen Receptor Positive Breast Cancer
Alliance Foundation Trials, LLC. 518
Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT04334330
What this trial is testing

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Who this might be right for
Breast CancerBrain Metastases
Sun Yat-sen University 34
Testing effectiveness (Phase 2)Study completedNCT01698918
What this trial is testing

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast Cancer
Novartis Pharmaceuticals 202
Testing effectiveness (Phase 2)Study completedNCT00134680
What this trial is testing

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

Who this might be right for
Metastatic Breast Cancer
Duke University 33
Early research (Phase 1)Study completedNCT01971515
What this trial is testing

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Who this might be right for
Solid Tumor
EMD Serono 101
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07786051
What this trial is testing

DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 80
Next Page